The adhesive gradually resorbs as the body heals—no second surgery needed.
From the tidal margins where oysters cling to rock against the pull of the sea, Chinese researchers have drawn a lesson in adhesion and applied it to one of medicine's oldest frustrations: the broken bone. A team in Hangzhou has developed Bone-02, an injectable adhesive that sets within minutes, holds with remarkable force, and then quietly disappears as the body heals itself — asking nothing more of the patient than time. Whether this biomimetic promise survives the rigors of international scrutiny remains the open question, but the ambition it represents — to let nature close what nature broke — is as old as medicine itself.
- Bone-02 sets in two to three minutes and delivers over 400 pounds of bonding force, offering surgeons a tool capable of stabilizing even shattered, multi-fragment fractures that metal hardware struggles to address.
- The adhesive's biodegradable design dissolves over roughly six months as natural healing progresses, eliminating the permanent foreign material, infection risk, and revision surgeries that plague conventional metal implants.
- Early results from more than 150 patients across multiple Chinese medical centers are described as promising, and a multicenter randomized controlled trial launched in September 2025 — but peer-reviewed international validation remains thin.
- Skepticism is warranted: coverage has largely flowed from state-affiliated media and hospital press releases, long-term mechanical and biocompatibility data are not yet public, and no load-bearing resorbable bone adhesive has previously reached proven clinical use.
- If independently validated, the technology could meaningfully reduce recovery times, surgical complications, and healthcare costs — with particular promise for elderly patients, complex trauma cases, and emergency or military medicine.
In September 2025, researchers at Sir Run Run Shaw Hospital in Hangzhou announced a material orthopedic surgeons have long sought: a bone adhesive that genuinely works in the human body. Called Bone-02, it is injected into a fracture through a small incision, hardens in two to three minutes with over 400 pounds of holding strength, and then biodegrades over roughly six months as natural healing takes over — leaving no implant, no permanent hardware, and no need for a second surgery.
The formula was inspired by oysters, which anchor themselves to rock in churning seawater using a biological cement of calcium carbonate and adhesive proteins. The Zhejiang University team reverse-engineered that chemistry into a dual-biomimetic compound capable of bonding in the wet, blood-filled environment of a fracture site. The adhesive was specifically designed for comminuted fractures — cases where bone shatters into multiple fragments that metal plates and screws struggle to stabilize.
More than 150 patients across several Chinese medical centers have received the treatment, with early outcomes described as excellent in both safety and effectiveness. The developers named it with a quiet joke: Bone-02 echoes '502,' the Chinese superglue brand synonymous with instant bonding.
Still, the evidence base carries real gaps. Coverage has come predominantly from state-affiliated media and hospital announcements rather than peer-reviewed international journals. Long-term data on how the adhesive performs under years of mechanical stress, and whether its breakdown products interact safely with surrounding tissue, has not been made public. A multicenter randomized controlled trial is underway, but its results remain forthcoming.
The potential, if validated, is considerable. Metal implants carry well-documented costs — infection, stress shielding, and the burden of additional operations. A resorbable injectable alternative could compress recovery timelines and reduce complications, particularly for elderly or trauma patients. Whether Bone-02 earns a place in global orthopedic practice or fades into the long catalogue of promising press releases will depend on what international peer review and longer-term follow-up reveal.
In September 2025, researchers at Sir Run Run Shaw Hospital in Hangzhou announced they had developed something orthopedic surgeons have chased for decades: a bone glue that actually works. The material, called Bone-02, is injected directly into a fracture, hardens in two to three minutes, and then dissolves naturally as the bone heals—eliminating the need for metal plates, screws, or a second surgery to remove them.
The inspiration came from an unlikely source: oysters. These mollusks spend their lives cemented to rocks in churning seawater, held fast by a biological adhesive made of calcium carbonate minerals and sticky proteins. The Zhejiang University team reverse-engineered that chemistry into a dual-biomimetic formula that could work inside the wet, bloody chaos of a human fracture site. A surgeon makes a small incision—two to three centimeters—injects the adhesive into the broken bone, and waits. Within minutes, the material bonds the fragments together with measurable force: over 400 pounds of holding strength, with shear strength around 0.5 megapascals and compressive strength near 10 megapascals.
What happens next is where Bone-02 diverges from traditional orthopedic hardware. As the body's natural healing processes take over—typically within six months—the adhesive gradually resorbs. There is no foreign material left behind. No permanent implant. No second operation. For patients who have endured weeks in casts or months of physical therapy, the promise is almost disarmingly simple.
The team, led by Associate Chief Physician Lin Xianfeng, specifically designed the adhesive to handle the fractures that conventional metal hardware struggles with: comminuted breaks, where bone shatters into multiple small fragments that are nearly impossible to stabilize with traditional plates and screws. According to the hospital, Bone-02 has already been tested on more than 150 patients across multiple Chinese medical centers. The early results are described as excellent in both safety and effectiveness. A multicenter randomized controlled trial began in September 2025.
But there are reasons to hold judgment. Most of the coverage so far has come from Chinese state-affiliated media and hospital press releases. Peer-reviewed publications in major international journals remain sparse. The long-term data—what happens after one or two years of normal mechanical stress—has not yet been made public. Questions linger about full biocompatibility and whether the breakdown products of the adhesive interact safely with surrounding tissue over extended periods. While similar bioadhesives exist for soft tissue or dental applications, a load-bearing, resorbable bone adhesive that reliably works in humans would genuinely be a first.
The potential impact, if validated, is substantial. Metal implants work, but they carry costs: infection risk, stress shielding (where the bone weakens because the metal bears all the load instead), and the trauma of additional surgeries. A successful injectable, resorbable alternative could compress recovery time, reduce complications, and lower healthcare costs—particularly for complex fractures, elderly patients, or in emergency and military settings. The developers even named it with a wink: Bone-02, a play on 502, the Chinese superglue brand that has become synonymous with instant adhesion.
China has demonstrated a capacity to move promising laboratory innovations into clinical practice faster than many expected. Whether Bone-02 becomes a routine tool in orthopedic surgery worldwide, or whether it joins the longer list of innovations that sounded transformative in a press release but never quite reached standard of care, remains to be seen. The next phase—international peer review, longer-term follow-up data, and replication in hospitals outside China—will determine whether this oyster-inspired adhesive truly changes how doctors treat broken bones.
Citas Notables
Early results are described as excellent in terms of safety and effectiveness, including cases of complex comminuted fractures.— Sir Run Run Shaw Hospital research team
La Conversación del Hearth Otra perspectiva de la historia
Why oysters? What made researchers look at how mollusks stick to rocks?
Oysters solve a problem that's almost identical to what surgeons face: bonding in a wet, moving environment where nothing should stick. Their adhesive works despite constant water flow and mechanical stress. That's the opposite of what most industrial glues can do.
And the fact that it dissolves—that's the real innovation, isn't it? Most bone implants are permanent.
Exactly. Metal plates and screws work, but they're foreign bodies. Your bone never fully heals around them. With Bone-02, once the natural healing takes over, the adhesive just... leaves. No second surgery. No permanent foreign material.
You mentioned 150 patients already. That's a substantial trial. Why the caution in the reporting?
Because most of what we know comes from Chinese state media and hospital announcements. We don't have independent peer-reviewed data yet. And we don't know what happens after a year or two of real mechanical stress—walking, lifting, the wear and tear of actual life.
What would change your mind? What would make this credible?
Publication in major international journals. Long-term follow-up data from independent researchers. Replication in hospitals outside China. And honest reporting of failures, not just successes. That's how medical innovations actually prove themselves.
If it works, what changes?
Everything. Fracture repair becomes simpler, faster, cheaper. Elderly patients recover quicker. Soldiers in the field could get better immediate care. The whole economics of orthopedic surgery shifts.